Clinical Trial Update: Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients [Phase 4]

View source ↗

Summary

Phase 4 study evaluating outcomes of early versus late G-CSF administration for primary prophylaxis in patients with non-Hodgkin's lymphoma to prevent neutropen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Neupogen (Filgrastim)
• ZARXIO (FILGRASTIM-SNDZ)

Snippet

Sponsor: Department of Medical Services Ministry of Public Health of Thailand | Conditions: Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor | Phase 4 | Status: NOT_YET_RECRUITING